Literature DB >> 11000249

Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.

M W Cho1, M K Lee, C H Chen, T Matthews, M A Martin.   

Abstract

We have previously reported that a chimpanzee infected with a primary human immunodeficiency virus type 1 (HIV-1) isolate (HIV-1(DH12)) developed an extremely potent virus-neutralizing antibody. Immunoglobulin G purified from this animal conferred sterilizing immunity following passive transfer to macaques which were subsequently challenged with simian immunodeficiency virus/HIV-1 chimeric virus strain DH12. In addition to being highly strain specific, the chimpanzee antiserum did not bind to the V3 loop peptide of HIV-1(DH12), nor did it block the interaction of gp120 with the CD4 receptor. When neutralization was examined in the context of virus particles carrying chimeric envelope glycoproteins, the presence of all five hypervariable regions (V1 to V5) was required for optimal neutralization. Virions bearing chimeric gp120 containing the V1-V2 and V4 regions of HIV-1(DH12) could also be neutralized, but larger quantities of the chimpanzee antiserum were needed to block infection. These results indicate that the HIV-1 gp120 epitope(s) targeted by the chimpanzee antiserum is highly conformational, involving surface elements contributed by all of the hypervariable domains of the envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000249      PMCID: PMC112409          DOI: 10.1128/jvi.74.20.9749-9754.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.

Authors:  P Putkonen; R Thorstensson; L Ghavamzadeh; J Albert; K Hild; G Biberfeld; E Norrby
Journal:  Nature       Date:  1991-08-01       Impact factor: 49.962

4.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate.

Authors:  M K Lee; J Heaton; M W Cho
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

6.  Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Authors:  B S Graham; T J Matthews; R B Belshe; M L Clements; R Dolin; P F Wright; G J Gorse; D H Schwartz; M C Keefer; D P Bolognesi
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

7.  Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.

Authors:  R L Willey; T Klimkait; D M Frucht; J S Bonifacino; M A Martin
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Authors:  P W Berman; J E Groopman; T Gregory; P R Clapham; R A Weiss; R Ferriani; L Riddle; C Shimasaki; C Lucas; L A Lasky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Authors:  E A Emini; W A Schleif; J H Nunberg; A J Conley; Y Eda; S Tokiyoshi; S D Putney; S Matsushita; K E Cobb; C M Jett
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

View more
  16 in total

1.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 2.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

4.  Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Wendy R Lee; Reza Sadjadpour; Olivia K Donau; Ronald Willey; Jason M Brenchley; Ranjini Iyengar; Alicia Buckler-White; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Authors:  Brett Spurrier; Jared M Sampson; Maxim Totrov; Huiguang Li; Timothy O'Neal; Constance Williams; James Robinson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

6.  Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.

Authors:  C H Chen; L Jin; C Zhu; S Holz-Smith; T J Matthews
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 9.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

10.  Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.

Authors:  Melissa E Laird; Tatsuhiko Igarashi; Malcolm A Martin; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.